- Home
- HWH vs CMMB Comparison
HWH vs CMMB Comparison
Compare HWH & CMMB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | HWH | CMMB |
|---|---|---|
| Founded | 2021 | 2004 |
| Country | United States | Israel |
| Employees | N/A | N/A |
| Industry | Other Pharmaceuticals | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 8.5M | 9.1M |
| IPO Year | 2022 | 2023 |
Fundamental Metrics
Financial Performance| Metric | HWH | CMMB |
|---|---|---|
| Price | $1.38 | $2.10 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $25.00 |
| AVG Volume (30 Days) | 21.3K | ★ 73.2K |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 101.67 |
| EPS | N/A | ★ 0.04 |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | $52.50 |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.90 | $0.87 |
| 52 Week High | $7.77 | $3.86 |
Technical Indicators
Market Signals| Indicator | HWH | CMMB |
|---|---|---|
| Relative Strength Index (RSI) | 47.97 | 62.86 |
| Support Level | $1.33 | $1.48 |
| Resistance Level | $1.50 | $2.24 |
| Average True Range (ATR) | 0.12 | 0.20 |
| MACD | 0.02 | 0.03 |
| Stochastic Oscillator | 67.07 | 95.01 |
Price Performance
Historical ComparisonAbout HWH HWH International Inc.
HWH International Inc is and its consolidated subsidiaries operate a food and beverage business in Singapore and South Korea. The F&B business operates four cafes, two of which are located in South Korea and two in Singapore, as well as an online healthy food store, serving customers in Singapore.
About CMMB Chemomab Therapeutics Ltd.
Chemomab Therapeutics Ltd is a clinical-stage biotech company, focusing on the discovery and development of therapeutics for fibrosis-related diseases with large unmet needs. The company's candidate, CM-101, is a monoclonal antibody that targets CCL24 and was shown to interfere with the underlying biology of liver, skin, and lung fibrosis using a novel and differentiated mechanism of action. CM-101 has demonstrated the potential to treat multiple severe and life-threatening fibrotic and inflammatory diseases. It is advancing three Phase 2 clinical trials in parallel for CM-101, treating rare fibrotic conditions.